Early Access

10-QPeriod: Q3 FY2009

CARDINAL HEALTH INC Quarterly Report for Q3 Ended Mar 31, 2009

Filed May 7, 2009For Securities:CAH

Summary

Cardinal Health, Inc. reported its third-quarter fiscal year 2009 results, showing a 9% increase in revenue to $24.9 billion, driven by pharmaceutical price appreciation and volume growth. However, operating earnings saw a decline of 14% for the quarter and 8% for the nine-month period, primarily due to lower gross margins, increased special items like restructuring charges, and higher interest expenses. The company is actively preparing for the planned spin-off of its clinical and medical products businesses into a new entity, CareFusion Corporation, targeting a summer 2009 completion. This separation, while intended to unlock value, also contributes to increased restructuring costs and introduces strategic uncertainties. Key financial figures indicate healthy revenue growth but highlight pressure on profitability, underscoring the impact of economic conditions and ongoing restructuring efforts.

Financial Statements
Beta

Key Highlights

  • 1Revenue increased by 9% year-over-year to $24.9 billion for the third quarter and $74.4 billion for the nine months ended March 31, 2009.
  • 2Operating earnings decreased by 14% to $496 million for the quarter and 8% to $1.46 billion for the nine months, impacted by lower gross margin and higher special items.
  • 3The company announced plans to spin off its clinical and medical products businesses into a new entity, CareFusion Corporation, targeting completion in summer 2009.
  • 4Restructuring charges, including those related to the spin-off and headcount reductions, significantly increased to $48.1 million for the quarter and $112.1 million for the nine months.
  • 5Net earnings decreased by 12% to $312.9 million ($0.87 per diluted share) for the quarter and 11% to $878.4 million ($2.43 per diluted share) for the nine months.
  • 6Cash and equivalents increased to $1.366 billion as of March 31, 2009, from $1.291 billion at the end of the prior fiscal year.
  • 7The company continues to manage significant litigation and regulatory matters, including an amended FDA Consent Decree and DEA investigations.

Frequently Asked Questions